Stage IV ROS1-positive lung adenocarcinoma: entrectinib-associated ventricular tachyarrhythmia treated with plasma exchange

Patient Info: Anonymized, Male, Under 40 | Stage IV

Biomarkers: ROS1-positive lung adenocarcinoma

Metastatic Site: not specified

As of October 2025, the patient survived severe entrectinib-associated ventricular tachyarrhythmia, was weaned from VA-ECMO by day 5 after therapeutic plasma exchange, and was discharged improved on day 13; later lung-cancer response was not described.

PubMed CentralRead more →

Stage IV Triple-Negative Breast Cancer: Nicole's Patient Story

Patient Info: Nicole, Female, 40s | Stage IV

Biomarkers: ER-negative; PR-negative; HER2-negative

Metastatic Site: liver

Nicole remained in active treatment for liver-metastatic triple-negative breast cancer, with meaningful response after switching to an antibody-drug conjugate and then undergoing mastectomy.

The Patient StoryRead more →

Stage IIIC ER-positive male breast cancer: mastectomy, chemotherapy, radiation, tamoxifen and abemaciclib

Patient Info: Anonymized, Male, 40s | Stage III

Biomarkers: ER 90% positive; PR 60% positive; HER2 score 0; Ki-67 15%; BRCA1 and BRCA2 no pathogenic variants; CEA 2.4 ng/mL; CA15-3 13.6 U/mL

He remained on tamoxifen and dose-adjusted abemaciclib; annual follow-up imaging, including non-contrast CT, showed no local or distant relapse.

PubMed CentralRead more →

Stage IV Invasive Ductal Carcinoma: Dalitso's Patient Story

Patient Info: Dalitso, Female, Under 40 | Stage IV

Metastatic Site: bone: spine, ribs, sternum, hip sockets

Dalitso had severe Stage IV bone-metastatic breast cancer with hospice-level symptoms and later bone progression, but subsequent imaging after a new treatment approach showed no visible active disease.

The Patient StoryRead more →

Stage IVA lung adenocarcinoma: fatal hemoptysis from pulmonary artery pseudoaneurysm after chemoradiotherapy

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: CEA 62 ng/mL; CA19-9 and neuron-specific enolase within normal limits; no molecular biomarkers reported

Metastatic Site: bone (11th thoracic vertebra)

The patient died from airway obstruction after massive hemoptysis caused by rupture of a pulmonary artery pseudoaneurysm that developed at the tumor-invaded pulmonary artery site after chemoradiotherapy.

PubMed CentralRead more →

HER2-positive Stage IV breast cancer: T-DM1 extravasation wound healed after multidisciplinary care

Patient Info: Anonymized, Female, Under 40 | Stage IV

Biomarkers: ER 90% positive; PR 70% positive; HER2 IHC 3+

Metastatic Site: pelvis

As of October 2025, the T-DM1 extravasation wound had almost fully healed within about 4 weeks, and the patient continued adjuvant T-DM1 through a port; longer cancer-control status was not described.

PubMed CentralRead more →

Stage IV BRCA2 Invasive Lobular Carcinoma: Marissa's Patient Story

Patient Info: Marissa, Female, Under 40 | Stage IV

Biomarkers: BRCA2 mutation; HER2-negative; PARP inhibitor resistance/progression described

Metastatic Site: bone marrow / bone; lymph nodes; skull lesions

Marissa’s breast tumors resolved after hormone blockers, but she remained in active treatment for Stage IV disease involving bone marrow/bone, lymph nodes, and skull lesions.

The Patient StoryRead more →

HER2-positive luminal B breast cancer with axillary tumor deposits: no recurrence after multimodal therapy

Patient Info: Anonymized, Female, 50s

Biomarkers: HER2-positive

After neoadjuvant therapy, mastectomy, axillary dissection, continued hormone therapy, and trastuzumab, she remained in good clinical condition with no detected recurrence.

PubMed CentralRead more →

Stage IV BRAF Colorectal Adenocarcinoma: Pio's Patient Story

Patient Info: Pio, Male, 50s | Stage IV

Biomarkers: BRAF V600 mutation

Metastatic Site: peritoneum; liver; left lung nodules

After initial chemotherapy produced mixed results and May imaging showed growth, BRAF/EGFR-directed treatment led to a marked improvement on July scans.

The Patient StoryRead more →

HER2-positive breast cancer: AC-THP treatment completed after infusion-port salvage

Patient Info: Anonymized, Female, 50s

Biomarkers: HER2-positive

She completed the planned breast-cancer treatment course after successful port salvage, had no recurrence of port-site skin thinning or exposure over the next 2 years, and the port was removed in October 2024.

PubMed CentralRead more →

Stage IVB EGFR-mutated lung adenocarcinoma with brain metastases: complete response and pathologic complete response

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: Lung adenocarcinoma with EGFR L858R, PD-L1 TPS 95%

Metastatic Site: brain

Brain metastases achieved complete response on imaging, and surgery after systemic therapy showed pathologic complete response, ypT0N0M0 with 0/13 lymph nodes involved.

PubMed CentralRead more →

ER/PR/HER2-positive breast cancer: gallbladder, liver, lung, pleural, and bone metastases after incomplete adjuvant therapy

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: Triple-positive breast cancer. Gallbladder metastasis kept ER/PR/HER2 positivity and Ki-67 >40%; markers supported breast origin.

Metastatic Site: gallbladder, liver, lung/pleura, bone

The patient died 3 years and 10 months after lumpectomy after metastatic ER/PR/HER2-positive breast cancer involved the gallbladder, liver, lungs/pleura, and bones following incomplete adjuvant therapy and loss to surveillance.

PubMed CentralRead more →

Stage IVA EGFR-mutant lung adenocarcinoma: response to triple targeted therapy and surgery

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: Initial EGFR exon 19 deletion; acquired BRAF V600E mutation in progressive lesion while EGFR exon 19 deletion persisted

Metastatic Site: pleura, pulmonary metastases; mediastinal and left…

As of May 2025, she continued osimertinib, dabrafenib, and trametinib after segmentectomy/lymphadenectomy, with 1% viable residual tumor in resected lung lesions, complete nodal pathologic response, and no disease progression.

PubMed CentralRead more →

Stage IVB ROS1-rearranged lung adenocarcinoma with bilateral ocular metastases: durable response to entrectinib

Patient Info: Anonymized, Male, 40s | Stage IV

Biomarkers: EZR-ROS1 fusion with mutation frequency 42.99%; TTF-1-positive in lung and left-eye tumor tissue

Metastatic Site: bilateral uveal/ocular metastases; bronchial lymph…

After about 3 years on entrectinib, systemic disease remained well controlled with partial remission, both eyes had best corrected visual acuity of 20/20, and no treatment-related discomfort or adverse events were reported.

PubMed CentralRead more →

Stage IV Invasive Lobular Carcinoma: Nikoo's Patient Story

Patient Info: Nikoo, Female, 40s | Stage IV

Biomarkers: BRCA1/2 negative; PIK3 mutation reported on liquid biopsy

Metastatic Site: Peritoneal/abdominal lining; abdominal lymph nodes

Nikoo had Stage I invasive lobular breast cancer in 2003 and developed Stage IV metastatic recurrence in 2022 after about 19 years. As of October 2025, she was living with metastatic lobular breast cancer, had moved through multiple systemic options, and was participating in a Phase 1 clinical trial.

The Patient StoryRead more →

Stage IV Colorectal Cancer: Starr's Survivor Story

Patient Info: Starr, Female, 40s | Stage IV

Metastatic Site: Liver; peritoneum; lymph nodes

Starr had Stage IV colon cancer involving the liver, peritoneum, and lymph nodes. After chemotherapy, targeted therapy, and 2 surgeries in early 2025, she was told scans and circulating-tumor testing showed no visible cancer. As of October 2025, she described being in remission.

The Patient StoryRead more →

EGFR L858R lung adenocarcinoma presenting as rectal and peritoneal metastases

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: Rectal/peritoneal tumors supported lung origin. Key result: EGFR L858R with TP53 mutations; no other actionable lung alteration reported.

Metastatic Site: rectum; peritoneum; omentum; mesentery; colonic wall

After transverse colostomy and confirmation of EGFR L858R-mutant lung adenocarcinoma metastasis, aumolertinib led to clinical stabilization; palliative radiotherapy was later given to the rectal lesion, but long-term follow-up was not yet available.

PubMed CentralRead more →

ALK-fusion lung adenocarcinoma with pleural progression: alectinib toxicity and switch to lorlatinib

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: EML4::ALK fusion positive

Metastatic Site: pleura

After pleural progression, disease was stable on ALK-targeted therapy; lorlatinib was tolerated after alectinib-related hemolysis and bradycardia resolved.

PubMed CentralRead more →

Stage IIA breast collision tumor: disease-free after surgery and adjuvant therapy

Patient Info: Anonymized, Female, 70+ | Stage II

Biomarkers: Two breast tumor parts were ER-positive; one HER2-low/negative and one HER2-positive. BRCA testing was suggested but not done.

Four years after surgery, she remained disease-free after mastectomy, adjuvant chemotherapy, HER2-targeted therapy, and endocrine therapy.

PubMed CentralRead more →

Stage IV Ovarian Cancer: Evelyn's Survivor Story

Patient Info: Evelyn, female | Stage IV

Biomarkers: HRD-positive

After chemotherapy and surgery, Evelyn reported an unremarkable final scan in May 2023 and then completed 2 years of Lynparza maintenance therapy guided by HRD-positive tumor testing.

Kidney complication after switching colorectal cancer chemotherapy regimens

Patient Info: Anonymized, Male, 70+ | Stage IV

Metastatic Site: liver

The cancer had worsening liver metastases when FTD/TPI began. After treatment was stopped, steroid therapy resolved edema within 1 month and proteinuria returned to baseline 2.5 months after admission; the later cancer course was not established.

PubMed CentralRead more →

Stage IV Breast Cancer: Dana's Patient Story

Patient Info: Dana, Female, 50s | Stage IV

Metastatic Site: Liver; bones; lymph nodes

As of October 2025, Dana was living with stable Stage IV metastatic breast cancer involving the liver, bones, and lymph nodes, controlled with targeted therapy and hormone blockers while also managing bipolar disorder and treatment-related mental health effects.

The Patient StoryRead more →

Stage IV sigmoid colon cancer: recurrence after FOLFOX, hepatectomy, and colectomy

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: Mismatch repair proficient; microsatellite stable; KRAS wild-type; BRAF wild-type; CEA 3.8 ng/mL at diagnosis

Metastatic Site: liver, lung

As of September 2025, metastatic sigmoid colon cancer had recurred in the lungs and remnant liver after initial FOLFOX, hepatectomy, and colectomy, requiring FOLFIRI plus cetuximab.

PubMed CentralRead more →

Stage IV EGFR Lung Cancer: Emily's Patient Story

Patient Info: Emily, Female, 40s | Stage IV

Biomarkers: EGFR mutation

Metastatic Site: Right lung; right 8th rib; sacrum; pancreas; brain

Emily had Stage IV EGFR-mutated lung cancer treated with daily targeted therapy, 4 rounds of chemotherapy, and later radiation. As of September 2025, she felt well and described being almost/basically in remission, but her cancer remained treatable rather than curable and she continued daily targeted therapy.

The Patient StoryRead more →